Biomark Diagnostics Inc. (20B)

Overview

Biomark Diagnostics Inc. is a pioneering entity in the field of oncology, dedicating its efforts towards the development of advanced cancer diagnostic platforms. Their focus is primarily on facilitating the early detection, continual monitoring, and effective treatment of cancer. Formed in 2014 and based in Richmond, Canada, Biomark Diagnostics Inc. positions itself at the forefront of cancer diagnostics through its unique combination of technology, research, and strategic partnerships. Their collaboration with Rubix LS is at the heart of their mission to revolutionize lung cancer screening and enhance breast cancer detection for women with dense breast tissues, showcasing their commitment to improving patient outcomes through early diagnosis.

Products and Services

Biomark Diagnostics Inc. specializes in the creation and development of diagnostic tools catered to the oncology sector. Their product offerings and services include:

• Liquid Biopsy Metabolic Panel Assay: This innovative assay is designed for the early-stage diagnosis of lung cancer. By analyzing metabolic markers in the blood, this tool allows for the detection of cancer at its earliest, most treatable stages, thereby significantly enhancing patient survival rates.
• Strategic Partnership with Rubix LS: Through this alliance, Biomark Diagnostics Inc. focuses on the development of diagnostic tools specifically engineered to improve lung cancer screening processes. This partnership also aims to advance breast cancer screening programs for women with dense breasts, utilizing cutting-edge technology to overcome the challenges traditionally associated with breast cancer detection in such cases.